Zilucoplan
Complement Inhibitors
Sold as ZILBRYSQ
- Drug class
- Complement Inhibitors
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 10
Overview
Zilucoplan is an active pharmaceutical ingredient in the Complement Inhibitors group (L04AJ). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 22, 2026 |
| CA Canada | Health Canada | 3 | June 10, 2025 |
| EU European Union | EMA | 1 | April 23, 2026 |
GBUnited Kingdom· MHRA
6 products
Uses
Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
How to take
CACanada· Health Canada
3 products
Uses
ZILBRYSQ (zilucoplan injection) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. 1 Dosing Considerations and 14 CLINICAL TRIALS). 1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
2 Geriatrics Geriatrics (≥ 65 years of age): Limited data are available to Health Canada regarding this age group. 3%) patients were 75 years or older. Based on pharmacokinetic analysis, age did not influence the pharmacokinetics of zilucoplan injection.
How to take
EUEuropean Union· EMA
1 product
Uses
Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
How to take
Sources & citations
- [1]MHRA (UK) · PLGB000390807 · revised May 22, 2026
- [2]Health Canada (DPD) · 02549220 · revised April 1, 2025
- [3]European Medicines Agency · EMEA/H/C/005450 · revised April 23, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.